Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 5/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607274 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2FNTAFNTBSTSANO1 | |
| SCHEMBL4971318 | 0.91 | REN (0.39) | SMN1; SMN2REN | |
| SCHEMBL3609024 | 0.88 | FNTA (0.39) | SMN1; SMN2FNTAFNTBSTSANO1 | |
| SCHEMBL3609025 | 0.88 | FNTA (0.39) | SMN1; SMN2FNTAFNTBSTSANO1 | |
| SCHEMBL3620859 | 0.88 | REN (0.43) | SMN1; SMN2FNTAFNTBSTSANO1 | |
| SCHEMBL3620857 | 0.88 | REN (0.43) | SMN1; SMN2FNTAFNTBSTSANO1 | |
| SCHEMBL13502919 | 0.88 | REN (0.43) | SMN1; SMN2FNTAFNTBSTSANO1 | |
| SCHEMBL3615882 | 0.87 | FNTA (0.42) | SMN1; SMN2FNTAFNTBSTSANO1 | |
| SCHEMBL3615881 | 0.87 | FNTA (0.42) | SMN1; SMN2FNTAFNTBSTSANO1 | |
| SCHEMBL3605863 | 0.84 | REN (0.54) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | SMN1; SMN2 1372/4885FNTA 1668/4885FNTB 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.